Reata Pharmaceuticals Inc (NASDAQ:RETA) was up 8.4% on Friday . The company traded as high as $29.88 and last traded at $29.56, with a volume of 279,184 shares changing hands. The stock had previously closed at $27.28.

A number of equities research analysts have weighed in on RETA shares. Cowen and Company started coverage on Reata Pharmaceuticals in a research report on Monday, June 20th. They set an “outperform” rating and a $22.00 target price for the company. Piper Jaffray Cos. started coverage on Reata Pharmaceuticals in a report on Monday, June 20th. They issued an “overweight” rating and a $33.00 price target on the stock. Zacks Investment Research upgraded Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Saturday, August 27th. Finally, Citigroup Inc. started coverage on Reata Pharmaceuticals in a report on Monday, June 20th. They issued a “buy” rating and a $32.00 price target on the stock.

The company’s market cap is $659.93 million. The stock’s 50-day moving average price is $16.98 and its 200 day moving average price is $18.02.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03. The business earned $12.40 million during the quarter. Analysts anticipate that Reata Pharmaceuticals Inc will post ($0.54) earnings per share for the current fiscal year.

In other news, Director R Kent Mcgaughy, Jr. purchased 308,220 shares of the firm’s stock in a transaction on Thursday, August 18th. The shares were bought at an average cost of $17.08 per share, for a total transaction of $5,264,397.60. Following the completion of the purchase, the director now directly owns 25,004 shares of the company’s stock, valued at $427,068.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cpmg Inc purchased 73,403 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were purchased at an average price of $19.26 per share, for a total transaction of $1,413,741.78. Following the completion of the purchase, the director now directly owns 113 shares of the company’s stock, valued at $2,176.38. The disclosure for this purchase can be found here.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

5 Day Chart for NASDAQ:RETA

Receive News & Ratings for Reata Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.